EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 9 ISSUE 2 – WINTER 2013

T his edition of European Oncology & Haematology has a leitmotif that accompanies patients and healthcare professionals on the path to cancer control, which is the quality of life of cancer patients, and the price that is continuously paid to improve the efficacy of treatment, to prolong survival and to increase the cure rate. Let […]

Over the past few decades, survival rates of cancer patients have increased impressively through the introduction of screening, new drugs and more personalised multi-modality treatments. This success in treating cancer has resulted in a large and rapidly increasing number of cancer survivors. Currently, there are over 13 million cancer survivors in the United States and […]

Cachexia is a complex metabolic disorder that results in progressive weight loss, muscle and adipose tissue wasting and inflammation and is frequently observed in patients with incurable malignancies.1 Weight loss in cancer patients results from reduction in adipose tissue and skeletal mass. Anorexia is defined as the loss of desire to eat. Although anorexia frequently […]

Over the last 10 years, the availability of neurokinin-1 receptor antagonists (NK1 RAs) has led to marked improvements in the treatment of chemotherapy-induced nausea and vomiting (CINV). In clinical trials with the NK1 RA aprepitant in combination with ondansetron and dexamethasone (DEX), more than 70 % of patients treated with highly emetic chemotherapy (HEC), such […]

Head and neck cancer encompasses tumours of different origins and types. Over 90 % of them are squamous cell carcinomas arising the epithelium of the upper aerodigestive tract, extending from the and oral cavities, down to the larynx and hypopharynx. Among the various clinical and pathological prognosticators, the presence of cervical nodal metastasis is the […]

Proceedings of a Satellite Symposium Held at the European Society for Medical Oncology 15th World Congress of Gastrointestinal Cancer in Barcelona, 3 July 2013

The management of colorectal cancer has continued to evolve over approximately one century. Without a doubt the most effective management strategy to combat this disease is prevention. This involves the identification of high-risk groups, dietary changes and dietary supplements.1 The next most effective management strategy is screening for disease to confirm a diagnosis of colon […]

Neuroendocrine tumours (NETs) is a collective term for a diverse range of neoplasms that arise from cells that originate in the endocrine and nervous systems and share common morphological and immunohistochemical features, including the presence of secretory granules. These tumours can secrete a variety of neuropeptides, which may or may not cause characteristic hormonal symptoms […]

In vulvar neoplasia, substantial improvements in therapy and care have been achieved during the last decade.1 Nevertheless, even minor surgical interventions cause multiple symptoms and side effects that affect a woman’s quality of life.2 The term ‘vulvar neoplasia’ includes vulvar intraepithelial neoplasia (VIN) and vulvar cancer.3,4 Vulvar neoplasia is a rare condition, but with an […]

Chronic lymphoproliferative disorders (CLPD) comprise several disorders that arise from a monoclonal proliferation of mature B or T cells. Among these entities, there are many that frequently involve the blood and are usually detected in routine blood analyses, the most frequent being chronic lymphocytic leukaemia (CLL). Before the advent of immunophenotyping, most CPLD were diagnosed […]

In the US, approximately 1 % of all breast cancer cases and less than 1 % of all male cancers are male breast cancer (MBC) cases. An estimated 2,240 cases of MBC will be diagnosed in the US in 2013 compared with 232,340 cases of female breast cancer (FBC).1 Due to its rarity, large prospective […]